Tyra Biosciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Tyra Biosciences sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Tyra Biosciences: 6 sponsored US clinical trials, 5 recruiting.
Tyra Biosciences sponsors 6 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is FGFR3 Gene Mutation, with 3 trials.
Upper-quartile sponsor footprint
Tyra Biosciences sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
NCT07265947
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06995677
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
NCT06915753
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
NCT06842355
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
NCT06160752
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
NCT05544552
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
What is open in the Tyra Biosciences pipeline
5 recruiting of 6 indexed (83% open).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: FGFR3 Gene Mutation (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Tyra Biosciences: open-pipeline peers nationwide
Peers matched on 6 registered trials and 83% open enrollment, not the therapeutic-area sidebar.
Tyra Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 83% open enrollment (± trial volume)
- Centessa Pharmaceuticals (UK) Limited · 83% recruiting · 6 trials
- Meyer Children's Hospital IRCCS · 83% recruiting · 6 trials
- SystImmune · 83% recruiting · 6 trials
- Johnson & Johnson Enterprise Innovation · 86% recruiting · 7 trials
Related
What to do with this Tyra Biosciences page
6 registered trials is a research-attention snapshot, not an endorsement of Tyra Biosciences or any single study.
- 5 of Tyra Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- FGFR3 Gene Mutation is the condition Tyra Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See FGFR3 Gene Mutation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Tyra Biosciences pipeline card: 6 registered trials from official public datasets.Report a data error.